Safety and Tolerability of Donepezil With Solifenacin in Patients With Dementia of the Alzheimer's Type Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07

Trial Profile

Safety and Tolerability of Donepezil With Solifenacin in Patients With Dementia of the Alzheimer's Type Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2017

At a glance

  • Drugs Donepezil/solifenacin (Primary) ; Solifenacin
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Chase Pharmaceuticals
  • Most Recent Events

    • 30 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 25 Jul 2016 Planned End Date changed from 1 Jul 2016 to 1 Dec 2016.
    • 25 Jul 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top